Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28600592 | 1.00 | F2RL3 (0.42) | F2RL3ALOX5APFEN1GPR119USP30 | |
| SCHEMBL28917974 | 1.00 | F2RL3 (0.42) | F2RL3ALOX5APFEN1GPR119USP30 | |
| SCHEMBL28775143 | 0.90 | ALOX5AP (0.43) | F2RL3ALOX5APFEN1GPR119USP30 | |
| SCHEMBL28775140 | 0.90 | ALOX5AP (0.43) | F2RL3ALOX5APFEN1GPR119USP30 | |
| SCHEMBL28601191 | 0.85 | USP30 (0.42) | USP30UCHL1ALDH1A1 | |
| SCHEMBL28601189 | 0.85 | USP30 (0.42) | USP30UCHL1ALDH1A1 | |
| SCHEMBL29808436 | 0.84 | ALOX5AP (0.45) | F2RL3ALOX5APFEN1GPR119USP30 | |
| SCHEMBL7368481 | 0.82 | FAAH (0.45) | GPR119USP30 | |
| SCHEMBL28775157 | 0.79 | ALOX5AP (0.42) | F2RL3ALOX5APFEN1GPR119USP30 | |
| SCHEMBL28775155 | 0.79 | ALOX5AP (0.42) | F2RL3ALOX5APFEN1GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| CN-107459510-B | Isoxazole compound and application thereof | 华东师范大学 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | IRAK1, IRAK2, IRAK4 | F2RL3 1891/4885ALOX5AP 4055/4885FEN1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.